The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease

被引:34
|
作者
Engelmann, Cornelius [1 ,2 ,3 ,4 ]
Tacke, Frank [1 ,2 ]
机构
[1] Charite Univ Med Berlin, Campus Virchow Klinikum CVK, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany
[2] Charite Univ Med Berlin, Campus Charite Mitte CCM, D-13353 Berlin, Germany
[3] Berlin Inst Hlth BIH, D-10178 Berlin, Germany
[4] UCL, Inst Liver & Digest Hlth, London NW3 2PF, England
关键词
NAFLD; NASH; SASP; senescence associated secretory phenotype; mitochondrial dysfunction; fibrosis; HEPATIC STELLATE CELLS; EXPERIMENTAL NASH; FIBROSIS; DYSFUNCTION; PROGRESSION; ACTIVATION; STEATOHEPATITIS; INFLAMMATION; HEPATOCYTES; MARKER;
D O I
10.3390/ijms23020652
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) represents an increasing global health burden. Cellular senescence develops in response to cellular injury, leading not only to cell cycle arrest but also to alterations of the cellular phenotype and metabolic functions. In this review, we critically discuss the currently existing evidence for the involvement of cellular senescence in NAFLD in order to identify areas requiring further exploration. Hepatocyte senescence can be a central pathomechanism as it may foster intracellular fat accumulation, fibrosis and inflammation, also due to secretion of senescence-associated inflammatory mediators. However, in some non-parenchymal liver cell types, such as hepatic stellate cells, senescence may be beneficial by reducing the extracellular matrix deposition and thereby reducing fibrosis. Deciphering the detailed interaction between NAFLD and cellular senescence will be essential to discover novel therapeutic targets halting disease progression.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome
    Grander, Christoph
    Grabherr, Felix
    Moschen, Alexander R.
    Tilg, Herbert
    VISCERAL MEDICINE, 2016, 32 (05) : 329 - 334
  • [42] Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy
    Tian, Yingxin
    Ni, Yiming
    Zhang, Ting
    Cao, Yemin
    Zhou, Mingmei
    Zhao, Cheng
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [43] Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
    Katsarou, Angeliki
    Tsioulos, Georgios
    Kassi, Eva
    Chatzigeorgiou, Antonios
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2024, 23 (04): : 621 - 636
  • [44] What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?
    Huber, Yvonne
    Galle, Peter R.
    Schattenberg, Joern M.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (01): : 68 - 73
  • [45] Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
    Linero, Paula Luque
    Castilla-Guerra, Luis
    EUROPEAN CARDIOLOGY REVIEW, 2024, 19
  • [46] Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
    Guo, Ziwei
    Wu, Qinjuan
    Xie, Pengfei
    Wang, Jiuchong
    Lv, Wenliang
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [47] The role of elastography in non-alcoholic fatty liver disease
    Liguori, Antonio
    Ainora, Maria E.
    Riccardi, Laura
    De Matthaeis, Nicoletta
    Pizzolante, Fabrizio
    Gasbarrini, Antonio
    Zocco, Maria A.
    Grieco, Antonio
    Rapaccini, Gianludovico
    Miele, Luca
    MINERVA GASTROENTEROLOGY, 2021, 67 (02): : 164 - 170
  • [48] The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease
    Winarto, Jessica
    Song, Dae-Geun
    Pan, Cheol-Ho
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [49] Innate and adaptive immunity in the context of non-alcoholic fatty liver disease
    Heinrich, Bernd
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (01): : 76 - 82
  • [50] Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis
    Sharma, Praveen
    Arora, Anil
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 5